Out of the 15 carcinoma cases with reduced or absent parafibromin immunoreactivity, only one sample displayed complete absence of expression whereas the remaining 14 cases exhibited partial loss (similar to the term “focal loss” proposed by Tan et al.)Interestingly, 3 out of 6 cases with established HRPT2 mutations displayed positive parafibromin expression, suggesting that cases with HRPT2 aberrations, not as a rule, display alterations in parafibromin immunoreactivity [22]. The gene discussed is CDC73; the disease is carcinoma.